Remove 2028 Remove Clinical Development Remove Pharmaceuticals
article thumbnail

The Competitive Edge of Biosimilars

DrugBank

For instance, Inflectra , a biosimilar of Remicade, underwent a comprehensive clinical development program, including a Phase III trial demonstrating comparable efficacy and safety to the reference product in patients with rheumatoid arthritis. billion by 2028.

article thumbnail

2021 Biotech IPOs Get Off to a Roaring Start

The Pharma Data

Syros Pharmaceuticals – Syros announced its IPO on January 20, offering 5.4 The proceeds will be used to fund its ongoing clinical and preclinical programs. It hopes to raise about $160 million in aggregate principal amount of 7.375% senior notes due 2025 and $270 million in aggregate principal amount of 7.250% senior notes due 2028.

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

Bayer, Broad Institute Extend Cardiovascular Drug Research Pact

The Pharma Data

The expanded agreement, which now stretches the collaboration through at least 2028, marks a new chapter in the two organizations’ efforts to harness cutting-edge genomic research, high-throughput screening platforms, and translational science to deliver precision medicines that could alter the course of chronic cardiovascular diseases.

article thumbnail

Pfizer Investor Day Features Significant Number of Pipeline Advances for COVID-19 Programs and Across Numerous Therapeutic Areas

The Pharma Data

27 key programs highlighted, including assets that could potentially contribute revenue by 2025 and others in the 2026-2028 time frame. UPDATES ON COVID-19 DEVELOPMENT PROGRAMS. In addition to the COVID-19 vaccine program, Pfizer aims to deliver five innovative vaccines by 2025, subject to clinical success and regulatory approval.

Vaccine 52